ConcertAI and NVIDIA Collaborate to Revolutionize Oncology Solutions

ConcertAI has joined forces with NVIDIA to advance translational and clinical development solutions through the ConcertAI CARA AI platform. Leveraging NVIDIA’s Inference microservices (NIM), including the recently introduced Llama 3 NIM, alongside CUDA-X microservices and the NeMo platform, this collaboration aims to redefine oncology research and treatment.

As reported by PR Newswire, ConcertAI has amassed the largest multi-modal oncology data repository over the past two years, now comprising data from over 8 million patients. December 2023 marked a significant acceleration when the ASCO CancerLinQ program integrated into ConcertAI under a long-term agreement. This collaboration, combined with ConcertAI’s partnerships in molecular diagnostics and radiology imaging with TeraRecon, has established a comprehensive research capability spanning various data modalities.

In January, ConcertAI introduced the CARA AI platform, supporting healthcare providers, research sites, and life science companies with next-generation AI SaaS solutions. The partnership with NVIDIA will further enhance ConcertAI’s mission to improve oncology research and patient care through AI-driven insights.

Also Read |  Revolutionary Snakebite Pill Tested in Kolkata Shows Encouraging Outcomes

Key initiatives include:

  1. High-performance AI Models for Clinical Development: Utilizing NVIDIA NIMs to deploy scalable, high-performance AI models, ConcertAI aims to enhance clinical trial patient matching, protocol automation, and real-time analytics.
  2. Large-scale Data Processing: Leveraging NVIDIA CUDA-X microservices to accelerate data processing, ConcertAI will efficiently manage the world’s largest curated oncology data set.
  3. Development of Precision Oncology and Medical LLMs: Trained on ConcertAI’s multi-modal data, these models will support advanced simulations for novel studies, clinical trial designs, and decision augmentation.

Jeff Elton, CEO of ConcertAI, emphasized the transformative potential of AI in oncology research, stating the partnership with NVIDIA will push the boundaries of AI capabilities in translational research, clinical development, and patient care. Kimberly Powell, VP of Healthcare at NVIDIA, highlighted the groundbreaking potential of integrating NVIDIA’s AI tools with ConcertAI’s platform to revolutionize clinical trials and outcome predictions.